LON:EVG

Evgen Pharma Share Forecast, Price & News

GBX 9.29

+0.19 (+2.09 %)

(As of 02/25/2021 10:12 AM ET)

Add

Compare

Today's Range

8.90

Now: GBX 9.29▼

9.29

50-Day Range

9.15

MA: GBX 10.13▼

11.24

52-Week Range

2.50

Now: GBX 9.29▼

Volume222,185 shs

Average Volume1.24 million shs

Market Capitalization£12.76 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.

Headlines

Evgen Shares Rise On Further Positive Test Results For SFX-01
January 22, 2021 | lse.co.uk

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial
October 23, 2020 | lse.co.uk

Nrf2 Pathway Activators Market Briefing and Future Outlook 2020 (Pandemic Impact Analysis) | Forward Pharma, Evgen Pharma, Lalilab, PharmAgra Labs
September 29, 2020 | marketwatch.com

Juvenescence Announces Licensing Agreement with Evgen Pharma plc
September 15, 2020 | finance.yahoo.com

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial
June 17, 2020 | www.lse.co.uk

Evgen Pharma Loss Slightly Wider On Expenses And Compensation
June 15, 2020 | www.lse.co.uk

BRIEF-Evgen Pharma FY Post Tax Loss £2.7 Mln
June 15, 2020 | www.reuters.com

BRIEF-Evgen Pharma Says In Talks With Potential Source Of Funds For COVID-19 Clinical Trial
May 15, 2020 | www.reuters.com

BRIEF-Evgen Pharma Announces Resignation Of Stephen Franklin As CEO
April 30, 2020 | www.reuters.com

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report Offers Growth Prospects 2019 to 2026
March 2, 2020 | www.marketwatch.com

Evgen Pharma Regulatory News
February 13, 2020 | www.lse.co.uk

Evgen Pharma, Rochester University To Advance SFX-01 For Trial
February 13, 2020 | www.lse.co.uk

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolLON:EVG

Previous Symbol

CUSIPN/A

CIKN/A

Webevgen.com

Phone+44-151-7053532

Employees9

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio6.71

Quick Ratio6.71

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£194,000.00

Price / Sales65.79

Cash FlowGBX 1.68 per share

Price / Cash Flow5.53

Book ValueGBX 1.90 per share

Price / Book4.89

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares137,397,000

Market Cap£12.76 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.60 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Evgen Pharma.

3.0 Community Rank

Outperform Votes
Evgen Pharma has received 193 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Evgen Pharma has received 134 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Evgen Pharma has received 59.02% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma and other stocks. Vote “Outperform” if you believe EVG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EVG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Evgen Pharma does not currently pay a dividend.
Dividend Growth
Evgen Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evgen Pharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Evgen Pharma is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evgen Pharma is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evgen Pharma has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

GBX 9.29

+0.19 (+2.09 %)

(As of 02/25/2021 10:12 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive EVG News and Ratings via Email

Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter.

Evgen Pharma (LON:EVG) Frequently Asked Questions

What stocks does MarketBeat like better than Evgen Pharma?

Wall Street analysts have given Evgen Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evgen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Evgen Pharma's earnings last quarter?

Evgen Pharma plc (LON:EVG) released its quarterly earnings data on Monday, June, 15th. The company reported ($2.10) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($2.10).
View Evgen Pharma's earnings history.

How has Evgen Pharma's stock been impacted by Coronavirus (COVID-19)?

Evgen Pharma's stock was trading at GBX 4.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVG stock has increased by 100.0% and is now trading at GBX 8.90.
View which stocks have been most impacted by COVID-19.

Who are Evgen Pharma's key executives?

Evgen Pharma's management team includes the following people:

Mr. Richard Anthony Moulson, CFO & Exec. Director (Age 59, Pay $85.4k)
Dr. Huw Jones, Chief Exec. Officer (Age 61)
Ms. Liz Jenkins, Regulatory Consultant
Dr. Thomas Morris, Consultant & Medical Advisor of Oncology
Prof. Albena Dinkova-Kostova, Independent Scientific Advisor
Prof. Giovanni Mann, Independent Scientific Advisor

Who are some of Evgen Pharma's key competitors?

Some companies that are related to Evgen Pharma include InMed Pharmaceuticals Inc. (IN.TO) (IN), Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Indiva Limited (NDVA.V) (NDVA), Cipher Pharmaceuticals Inc. (CPH.TO) (CPH), Harvest One Cannabis (HVT), Eve & Co Incorporated (EVE), SugarBud Craft Growers Corp. (SUGR.V) (SUGR), NeutriSci International Inc. (NU.V) (NU), Aequus Pharmaceuticals Inc. (AQS.V) (AQS), Lattice Biologics (LBL), (THCX.V) (THCX), 31444 (GLH) and 438280 (ACG).
View all of EVG's competitors.

What other stocks do shareholders of Evgen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evgen Pharma investors own include MOTIF BIO PLC/S (MTFB), Capital & Counties Properties PLC (CAPC.L) (CAPC), Obtala (OBT), Tertiary Minerals (TYM), Veltyco Group (VLTY), Atalaya Mining (AYM), AllianceBernstein Global High Income Fund (AWF), Advent Convertible and Income Fund (AVK), Ares Dynamic Credit Allocation Fund (ARDC) and UBS ETRACS Alerian MLP Index ETN (AMU).

What is Evgen Pharma's stock symbol?

Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

How do I buy shares of Evgen Pharma?

Shares of EVG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Evgen Pharma's stock price today?

One share of EVG stock can currently be purchased for approximately GBX 8.90.

How much money does Evgen Pharma make?

Evgen Pharma has a market capitalization of £12.23 million and generates £194,000.00 in revenue each year.

How many employees does Evgen Pharma have?

Evgen Pharma employs 9 workers across the globe.

What is Evgen Pharma's official website?

The official website for Evgen Pharma is evgen.com.

Where are Evgen Pharma's headquarters?

Evgen Pharma is headquartered at The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom.

How can I contact Evgen Pharma?

Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532.

This page was last updated on 2/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here